Clinical trials: Uterine Neoplasm
Cervical Cancer, Colorectal Cancer
89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
A prospective, open-label, phase 2 study to explore CAIX expression through 89Zirconium-labelled girentuximab deferoxamine (89Zr-girentuximab) PET/CT imaging in patients with solid tumors.
- Conditions
- Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- STARBURST (NCT05563272)
- Testing
- 89Zr-girentuximab for PET/CT imaging of CAIX positive tumors
- Where
- 10 sites in United States
- Volunteers
- 11 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Ltd
Pelvic Cancer, Ovarian Cancer
Ultrasound-guided Tru-Cut Biopsy in Pelvic Masses.
In a transvaginal tru-cut biopsy, guided by ultrasound, a needle is inserted through the vaginal wall into a pelvic lesion and a few pieces of tissue are obtained for examination.
- Conditions
- Pelvic Cancer, Ovarian Cancer, Cervical Cancer, Uterus Cancer
- Trial name
- NCT05610501
- Testing
- Ultrasound guided tru-cut biopsy
- Where
- 4 sites in Belgium, Czechia and 2 more
- Volunteers
- 200 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Atypical Squamous Cells of Undetermined Significance, Cervical Cancer
SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells
This randomized phase II trial is studying how well SGN-00101 vaccine works compared to a placebo in treating human papillomavirus and preventing cervical cancer in patients with abnormal cervical cells.
- Conditions
- Atypical Squamous Cells of Undetermined Significance, Cervical Cancer, High-grade Squamous Intraepithelial Lesion, Low-grade Squamous Intraepithelial Lesion
- Trial name
- NCT00091130
- Testing
- HspE7, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- National Cancer Institute (NCI)
Uterine Fibroids
Evaluation of a Hysteroscopic Method With Vaporization in the Hysteroscopic Treatment of Submucosal Uterine Fibroids
Operative hysteroscopy (OH) is an endoscopic technique for the treatment of benign intrauterine lesions and in particular uterine fibroids.
- Trial name
- VAPOHYSTERO (NCT05078307)
- Testing
- OHR VS OHV
- Where
- France
- Volunteers
- 54 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Cervical Intraepithelial Neoplasia
Safety Study to Test the Safety of HspE7 and Poly-ICLC Given in Patients With Cervical Intraepithelial Neoplasia
The purpose of this study is to determine the safety and tolerability of HspE7 and Poly-ICLC when given together
- Trial name
- NCT00493545
- Testing
- HspE7 and Poly-ICLC
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- Nventa Biopharmaceuticals Corporation
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma
Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase II clinical trial studies the effect of lenvatinib, pembrolizumab, and paclitaxel in treating patients with endometrial, epithelial ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent).
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Endometrial Carcinoma
- Trial name
- NCT04781088
- Testing
- Lenvatinib, Paclitaxel, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Floor Backes, MD
Cervical Cancer
Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer
To evaluate the efficacy and safety of tislelizumab combined with concurrent chemoradiotherapy in first-line treatment of stage IIIC2 cervical cancer.
- Trial name
- NCT05511623
- Testing
- tislelizumab, concurrent chemoradiotherapy
- Where
- China
- Volunteers
- 112 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Infections, Papillomavirus
Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs
Human Papillomavirus (HPV) infection has been established as a necessary cause of cervical cancer. GlaxoSmithKline (GSK) Biologicals has developed an HPV vaccine (580299) which targets the 2 most common oncogenic HPV types…
- Trial name
- NCT00541970
- Testing
- Cervarix
- Where
- 25 sites in Canada, Germany
- Volunteers
- 961 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cervical Cancer
Lab-on-a-chip Detection of Cervical Cancer Tumour Markers
This study aims to establish whether tumour markers measured from cytological samples can improve cervical cancer detection both prior to treatment and after treatment during follow up.
- Trial name
- MODULAR (NCT03380741)
- Testing
- Tumour markers detection
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust
Progesterone Induced Blocking Factor in Endometrial Cancer
Progesterone Induced Blocking Factor Expression Levels in Endometrial Cancer Cells.
Immune system suppression effect of Progesterone Induced Blocking Factor(PIBF), it could be questionable whether tumor cells express PIBF for escape of immune system.
- Trial name
- NCT02852954
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Kayseri Education and Research Hospital
Cervical Intraepithelial Neoplasia Grade 2/3, Neoplasm Cervix
Evaluation of in Vitro Devices on Self-collected Vaginal Swab and Urine Sample for Testing of Human Papilloma Virus
The European VALHUDES study is a Clinical Performance /Diagnostic Test Accuracy Study that aims to evaluate whether HPV testing with new assays performed on self-samples, collected by means of a vaginal and a urine collection…
- Conditions
- Cervical Intraepithelial Neoplasia Grade 2/3, Neoplasm Cervix, Carcinoma in Situ, Carcinoma Cervix Uterine
- Trial name
- EU-VALHUDES (NCT04312737)
- Testing
- Self-Collecting Devices, In Vitro Diagnostic Assays
- Where
- 6 sites in Ireland, Italy and 1 more
- Volunteers
- 600 people
- Sponsor
- Hiantis Srl
Neoplasms, Prostatic Neoplasms, Castration-Resistant
HTL0039732 in Participants With Advanced Solid Tumours
The purpose of this trial is to evaluate a new drug, HTL0039732, that will be administered on its own (as a monotherapy) and in combination with atezolizumab or with other approved anti-cancer therapies, in participants with…
- Conditions
- Neoplasms, Prostatic Neoplasms, Castration-Resistant, Stomach Neoplasms, Esophageal Neoplasms
- Trial name
- NCT05944237
- Testing
- HTL0039732 Capsules, HTL0039732 Capsules or HTL0039732 tablets and atezolizumab infusion
- Where
- 6 sites in United Kingdom
- Volunteers
- 150 people
- Sponsor
- Cancer Research UK
Stage IA Uterine Corpus Cancer, Stage IB Uterine Corpus Cancer
Physical Activity Behavioral Intervention in Obese Endometrial Cancer Survivors
This randomized clinical trial studies a physical activity behavioral intervention in obese endometrial cancer survivors. Learning about physical activity behavior while participating in a fitness class may help increase physical…
- Conditions
- Stage IA Uterine Corpus Cancer, Stage IB Uterine Corpus Cancer, Stage II Uterine Corpus Cancer, Stage IIIA Uterine Corpus Cancer
- Trial name
- NCT02575872
- Testing
- Exercise Intervention
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Albert Einstein College of Medicine
Endometrial Neoplasms, Endometrial Cancer Stage I
Comparison of Two-Position and Four-Position Cervical Injection Techniques for Sentinel Lymph Node Mapping in Endometrial Cancer Using Methylene Blue
This clinical trial evaluates lymph node mapping in newly diagnosed endometrial cancer patients undergoing surgery. The standard technique uses a 2-point methylene blue cervical injection.
- Conditions
- Endometrial Neoplasms, Endometrial Cancer Stage I, Sentinel Lymph Node, Metastasis
- Trial name
- NCT07040657
- Testing
- Sentinel Lymph Node Detection/Cervical Methylene Blue Injection
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Dokuz Eylul University
Head and Neck Cancer, Melanoma
Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study
This is an open-label, dose escalation study of the safety and tolerability of Recombinant oncolytic adenovirus L-IFN injection（YSCH-01） when administered via intratumoral injection in patients with advanced solid tumors.
- Conditions
- Head and Neck Cancer, Melanoma, Breast Cancer, Bladder Cancer
- Trial name
- YSCH-01 (NCT05180851)
- Testing
- Recombinant L-IFN adenovirus injection
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Shanghai Fengxian District Central Hospital
Ovarian Cancer, Relapsed Ovarian Cancer
Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer
ACTOv will compare standard 3-weekly carboplatin (AUC5), to carboplatin delivered according to an AT regimen. The AT regimen will modify carboplatin dose according to changes in the clinical-standard serum biomarker CA125 as a…
- Conditions
- Ovarian Cancer, Relapsed Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- ACTOv (NCT05080556)
- Testing
- Carboplatin
- Where
- United Kingdom
- Volunteers
- 80 people
- Sponsor
- University College, London
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic or Breast Cancer
This clinical trial tests feasibility, acceptability and how well a virtual mental health intervention, compared to enhanced usual care consisting of an educational intervention, works to address fear of progression for women…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Endometrial Carcinoma, Endometrial Endometrioid Adenocarcinoma
- Trial name
- NCT07226102
- Testing
- Behavioral Intervention, Educational Intervention, Internet-Based Intervention
- Where
- 12 sites in United States
- Sponsor
- City of Hope Medical Center
Advanced Endometrial Cancer, Sarcoma of Uterus
Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.
This clinical study plans to enroll 69 endometrial cancer patients and 5-10 uterine sarcoma patients. The trial is divided into a lead-in phase and a main phase.
- Trial name
- NCT05481645
- Testing
- TQB2450 injection, Anlotinib Hydrochloride Capsule, Carboplatin Injection
- Where
- 11 sites in China
- Volunteers
- 71 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Cervical Cancer
Liposomal Doxorubicin in Treating Patients With Persistent or Recurrent Cancer of the Cervix
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness liposomal doxorubicin in treating patients who have…
- Trial name
- NCT00030472
- Testing
- pegylated liposomal doxorubicin hydrochloride
- Where
- 17 sites in United States, Norway
- Sponsor
- Gynecologic Oncology Group
Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC)
QLS5132 Combination Therapy in Advanced Solid Tumors
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and effectiveness of the investigational drug QLS5132 (injectable) in combination with other therapies for participants with advanced…
- Conditions
- Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC), Endometrial Cancer, Advanced Solid Tumors
- Trial name
- NCT07453394
- Testing
- QLS5132; Bevacizumab, QLS5132; Platinum; Bevacizumab, QLS5132; Olaparib; Bevacizumab
- Volunteers
- 626 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.